Kneat

Kneat is a public company (TSX:KSI, OTCQX:KSIOF) selling digital validation software to pharmaceutical and life sciences companies. Founded in 2007, the company spent 8 years developing its Kneat Gx platform before its first customer delivery in 2015. The platform is built on 900,000 lines of purpose-built code for GxP validation.

The company describes Kneat Gx as "the world's most developed validation software solution," built to move pharmaceutical manufacturers from paper-based validation to digital, cloud-based workflows while maintaining FDA 21 CFR Part 11 and EU Annex 11 compliance. The platform addresses computer system validation (CSV) and computer software assurance (CSA) requirements across the validation lifecycle.

8 of the top 10 life sciences companies use Kneat's platform. The company went public on the Toronto Stock Exchange in 2016 and trades on OTCQX in the United States. As of Q3 2025, Kneat reported Annual Recurring Revenue (ARR) of $68.6M (up 37% year-over-year) with a market capitalization of $380M.

The company is led by CEO Eddie Ryan (co-founder, former pharmaceutical engineer turned SaaS leader), with co-founders Brian Ahearne (Director of Information Security) and Kevin Fitzgerald (Chief Innovation Officer, former Pfizer). Kneat holds ISO/IEC 9001:2015 and ISO/IEC 27001:2022 certifications and is an ISPE Platinum member. The company has won the Deloitte Ireland Fast 50 award four times.

100% of Kneat's business is pharmaceutical and life sciences validation software; it does not serve other industries or offer general-purpose quality management software.

Kneat serves 8 of the top 10 life sciences companies globally. Named customers include Merck Sharp & Dohme (MSD), Pfizer, and HCL Technologies, spanning pharmaceutical manufacturers, biotechnology companies, and contract development and manufacturing organizations (CDMOs).

Kneat markets itself as a validation software specialist with expertise in FDA 21 CFR Part 11, EU Annex 11, computer system validation (CSV), and computer software assurance (CSA). The platform is built on 900,000 lines of code developed for pharmaceutical compliance requirements.

Merck implemented Kneat Gx across 27 sites covering 7 validation processes, with a reported 50%+ cycle time reduction. HCL Technologies reported $81M in cost savings on CSV activities.

Kneat is an ISPE Platinum member and holds ISO/IEC 9001:2015 and ISO/IEC 27001:2022 certifications from NSAI (National Standards Authority of Ireland).

Q3 2025 revenue was $16.1M, up 26% year-over-year, with SaaS revenue of $15.2M, up 33% year-over-year. Trailing twelve-month revenue as of June 2025 was $40.5M. Annual Recurring Revenue (ARR) reached $68.6M as of September 2025, up 37% year-over-year. Market capitalization was approximately $380M as of September 2025.

Kneat completed its initial public offering on the Toronto Stock Exchange in 2016. Post-IPO equity financing totals $35.6M, including a $20M round in February 2024 led by a Cormark Securities syndicate.

SaaS revenue grew faster than total revenue in the quarter (33% versus 26%). The company has won the Deloitte Ireland Fast 50 award four times.

Kneat's product portfolio centers on the Kneat Gx digital validation software platform, which took 8 years to develop before its first customer delivery in 2015. The platform is built on 900,000 lines of purpose-built code for pharmaceutical GxP validation.

Kneat sells a single product rather than a multi-product suite. Kneat Gx covers the validation lifecycle end-to-end, from requirements definition through execution, review, approval, and ongoing maintenance, supporting both computer system validation (CSV) and computer software assurance (CSA) methodologies.

Capabilities include a real-time Requirements Traceability Matrix (RTM) with auto-generated updates, Collections (virtual war rooms for remote audits), Boolean search across validation documents, electronic signatures, audit trails, direct integration with manufacturing equipment and laboratory instruments, and offline execution for areas without continuous network connectivity.

Certified VEQTOR packs offer pre-configured validation templates for 6-week implementations; custom implementations typically take 12–15 weeks. Version 9.2 is the most recent release referenced.

Kneat Academy provides training and user certification. Customer Success and Consulting services support implementation, validation, and ongoing platform optimization. Support is delivered through Zendesk.

The platform addresses FDA's 2022 draft guidance for Computer Software Assurance (CSA).

Kneat is an ISPE (International Society for Pharmaceutical Engineering) Platinum member, with access to GAMP guidance development and pharmaceutical industry thought leadership through that membership.

The platform is delivered as a cloud-hosted SaaS solution with API integration capabilities for manufacturing equipment, laboratory instruments, and enterprise systems. Cloud provider partnerships (AWS, Azure, GCP) are undisclosed. Kneat Gx supports API-based integrations with quality management systems (QMS), document management systems, and enterprise resource planning (ERP) solutions, plus direct equipment integration for automated data collection from manufacturing and laboratory instruments.

Zendesk is the customer support ticketing and knowledge base partner. No partnership beyond ISPE membership and these technology integrations is disclosed.

Support is delivered through Zendesk, covering ticket management, knowledge base access, and issue resolution. Support availability (24/7 versus business hours) and regional coverage are undisclosed.

Customer Success and Consulting services cover implementation, validation assistance, training, and ongoing platform optimization. Two implementation approaches are available: certified VEQTOR packs for standardized 6-week deployments, and custom implementations that typically take 12–15 weeks. Implementation services include platform configuration, validation protocol development, migration planning from paper-based or legacy validation systems, system validation assistance, and user acceptance testing support.

Kneat Academy runs structured training programs for user certification and platform proficiency, covering validation methodology, platform functionality, and best practices for digital validation workflows.

Dedicated Customer Success teams support ongoing platform optimization, validation process improvement, and business value realization. Kneat was named a G2 Fall 2025 Leader in the Relationship Index (Ease of Doing Business, Likely to Recommend, Quality of Support).

User conferences, forums, and customer advisory boards are undisclosed.

Kneat holds ISO/IEC 9001:2015 (quality management, certified since 2012) and ISO/IEC 27001:2022 (information security) certifications from NSAI (National Standards Authority of Ireland).

The company has won the Deloitte Ireland Fast 50 award four times. G2 Fall 2025 recognition includes Leader in the Pharma & Biotech Grid Report, Leader in the Relationship Index, second place in the Usability Index, and Leader in the Mid-Market Grid Report.

Leadership: CEO Eddie Ryan (co-founder, pharmaceutical engineer turned SaaS leader), Brian Ahearne (co-founder, Director of Information Security), and Kevin Fitzgerald (co-founder, Chief Innovation Officer, former Pfizer). The founding team combines pharmaceutical industry background with software development and information security experience.

Kneat is an ISPE Platinum member. It has traded on TSX:KSI and OTCQX:KSIOF since its 2016 IPO, subject to public-company financial disclosure and governance requirements. 8 of the top 10 life sciences companies are customers.

As a TSX-listed public company, Kneat provides quarterly financial disclosures, investor presentations, and regular business updates. Q3 2025 results: $16.1M revenue (up 26% year-over-year), $68.6M ARR (up 37% year-over-year), and $380M market capitalization.

The website includes product documentation, case studies with quantified results (Merck 50%+ cycle time reduction across 27 sites, HCL Technologies $81M cost savings, an 88% time reduction on URS creation for a biotech customer), validation resources, and the Kneat Academy training platform, product positioning content, and an investor relations section, maintained with current financial disclosures and product updates (Version 9.2 referenced).

G2 Fall 2025 recognition: a 98/100 satisfaction score, Leader in the Pharma & Biotech Grid Report, Leader in the Relationship Index, and second place in the Usability Index.

ISPE Platinum membership gives visibility at pharmaceutical industry events and standards development activities. The company has won the Deloitte Ireland Fast 50 award four times.

Press release frequency and social media activity are undisclosed. Public-company status requires regular financial and business disclosures.